BUSINESS
Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
Sun Pharma Japan is set to augment its marketing organization and drug pipeline in a bid to solidify its business base. While the company’s operations currently revolve around dermatology, it is aiming its sights on…

LATEST

October 27, 2021
The Japan Generic Medicines Association (JGA) on October 25 announced a set of measures aimed at recovering trust in generic drugs, which were sorted under five themes including the strengthening of compliance and governance and…
October 27, 2021
Nobelpharma is in discussions with regulatory authorities to launch three in-house products including Rapalimus Gel (sirolimus) in the US, Chinese, and European markets, R&D head Shigeki Shimasaki said at a media seminar on October 26.The three products being planned for…
October 27, 2021
Solasia Pharma said on October 26 that it has terminated its license agreement with Meiji Seika Pharma for Japan rights to darinaparsin, a drug candidate for peripheral T-cell lymphoma (PTCL), while announcing a new pact with Nippon Kayaku.Solasia signed the…
By Yasuchika Hisatani

In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…

By Philip Carrigan

If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA